Targeting carcinogenesis: A role for the prolyl isomerase Pin1?

Molecular Carcinogenesis

Volumn 45, Issue 6, 2006, Pages 397-402

  Lu, Kun Ping ^a,b   Suizu, Futoshi ^a   Zhou, Xiao Zhen ^a   Finn, Greg ^a   Lam, Prudence ^a   Wulf, Gerburg ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Laboratory of Cancer Biology   (United States)

Author keywords

Anticancer target; Carcinogenesis; Phosphorylation signaling; Pin1; Prolyl isomerase

Indexed keywords

PEPTIDYLPROLYL ISOMERASE PIN1; PROLINE; PROLYL ISOMERASE; SERINE; THREONINE; TUMOR MARKER; UNCLASSIFIED DRUG;

CARCINOGENESIS; CATALYST; CELL PROLIFERATION; CELL TRANSFORMATION; CONFERENCE PAPER; CONFORMATIONAL TRANSITION; GENOMIC INSTABILITY; KNOCKOUT MOUSE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION;

CATALYSIS; CELL TRANSFORMATION, NEOPLASTIC; CENTROSOME; HUMANS; PEPTIDYLPROLYL ISOMERASE;

MUS MUSCULUS;

EID: 33745002500     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20216     Document Type: Conference Paper

References (71)

1. Lu KP. Pinning down cell signaling, cancer and Alzheimer's disease. Trends Biochem Sci 2004;29:200-209.
2. Wulf G, Finn G, Suizu F, Lu KP. Phosphorylation-specific prolyl isomerization: Is there an underlying theme? Nature Cell Biol 2005;7:435-441.
3. Lu KP, Hanes SD, Hunter T. A human peptidyl-prolyl isomerase essential for regulation of mitosis. Nature 1996; 380:544-547.
4. Yaffe MB, Schutkowski M, Shen M, et al. Sequence-specific and phosphorylation-dependent proline isomerization: A potential mitotic regulatory mechanism. Science 1997;278: 1957-1960.
5. Schutkowski M, Bernhardt A, Zhou XZ, et al. Role of phosphorylation in determining the backbone dynamics of the serine/threonine-proline motif and Pin1 substrate recognition. Biochemistry 1998:37:5566-5575.
6. Lu KP, Liou YC, Zhou XZ. Pinning down the praline-directed phosphorylation signaling. Trends Cell Biol 2002;12:164-172.
7. Weiwad M, Kullertz G, Schutkowski M, Fischer G. Evidence that the substrate backbone conformation is critical to phosphorylation by p42 MAP kinase. FEBS Lett 2000;478: 39-42.
8. Brown NR, Noble ME, Endicott JA, Johnson LN. The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases. Nat Cell Biol 1999;1:438-443.
9. Zhou XZ, Kops O, Werner A, et al. Pin1-dependent prolyl isomerization regulates dephosphorylation of Cdc25C and tau proteins. Mol Cell 2000;6:873-883.
10. Ranganathan R, Lu KP, Hunter T, Noel JP. Structural and functional analysis of the mitotic peptidyl-prolyl isomerase Pin1 suggests that substrate recognition is phosphorylation dependent. Cell 1997;89:875-886.
11. Lu PJ, Zhou XZ, Shen M, Lu KP. A function of WW domains as phosphoserine- or phosphothreonine-binding modules. Science 1999;283:1325-1328.
12. Verdecia MA, Bowman ME, Lu KP, Hunter T, Noel JP. Structural basis for phosphoserine-proline recognition by group IV WW domains. Nat Struct Biol 2000;7:639-643.
13. Wintjens R, Wieruszeski JM, Drobecq H, et al. 1H NMR study on the binding of Pin1 Trp-Trp domain with phosphothreonine peptides. J Biol Chem 2001;276:25150-25156.
14. Stukenberg PT, Kirschner MW. Pin1 acts catalytically to promote a conformational change in Cdc25. Mol Cell 2001; 7:1071-1083.
15. Pastorino L, Sun A, Lu PJ, et al. The prolyl isomerase Pin1 regulates amyloid precursor protein processing and amyloid-beta production. Nature 2006;440:528-534.
16. Zhou XZ, Lu PJ, Wulf G, Lu KP. Phosphorylation-dependent prolyl isomerization: A novel signaling regulatory mechanism. Cell Mol Life Sci 1999;56:788-806.
17. Ryo A, Liou YC, WuIf G, Nakamura N, Lee SW, Lu KP. Pin1 is an E2F target gene essential for the Neu/Ras-induced transformation of mammary epithelial cells. Mol Cell Biol 2002;22:5281-5295.
18. You H, Zheng H, Murray SA, et al. IGF-1 induces Pin1 expression in promoting cell cycle S-phase entry. J Cell Biochem 2002;84:211-216.
19. Lu PJ, Zhou XZ, Liou YC, Noel JP, Lu KP. Critical role of WW domain phosphorylation in regulating its phosphoserine-binding activity and the Pin1 function. J Biol Chem 2002; 277:2381-2384.
20. Sultana R, Boyd-Kimball D, Poon HF, et al. Oxidative modification and down-regulation of Pin1 in Alzheimer's disease hippocampus: A redox proteomics analysis. Neurobiol Aging 2005: June 9 Epub.
21. Eckerdt F, Yuan J, Saxena K, et al. Polo-like kinase 1-mediated phosphorylation stabilizes Pin1 by inhibiting its ubiquitination in human cells. J Biol Chem 2005;280:36575-36583.
22. Wulf GM, Ryo A, Wulf GG, Lee SW, Niu T, Lu KP. Pin1 is overexpressed in breast cancer and potentiates the transcriptional activity of phosphorylated c-Jun towards the cyclin D1 gene. EMBO J 2001;20:3459-3472.
23. Ryo A, Nakamura N, Wulf G, Liou YC, Lu KP. Pin1 regulates turnover and subcellular localization of beta-catenin by inhibiting its interaction with APC. Nature Cell Biol 2001;3: 793-801.
24. Liou YC, Ryo R, Huang HK, et al. Loss of Pin1 function in the mouse causes phenotypes resembling cyclin D1-null phenotypes. Proc Natl Acad Sci USA 2002;99:1335-1340.
25. Ryo A, Liou YC, Lu KP, Wulf G. Prolyl isomerase Pin1: A catalyst for oncogenesis and a potential therapeutic target in cancer. J Cell Sci 2003;116:773-783.
26. Lu PJ, Wulf G, Zhou XZ, Davies P, Lu KP. The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein. Nature 1999;399:784-788.
27. Liou Y-C, Sun A, Ryo A, et al. Role of the prolyl isomerase Pin1 in protecting against age-dependent neurodegeneration. Nature 2003;424:556-561.
28. Ayala G, Wang D, Wulf G, et al. Pin1 is a novel prognostic marker in prostate cancer. Cancer Res 2003;63:6244-6251.
29. Miyashita H, Uchida T, Mori S, Echigo S, Motegi K. Expression status of Pin1 and cyclins in oral squamous cell carcinoma: Pin1 correlates with Cyclin D1 mRNA expression and clinical significance of cyclins. Oncol Rep 2003;10:1045-1048.
30. Atchison FW, Means AR, Capel B. Spermatogonial depletion in adult Pin1-deficient mice: Pin1 regulates the timing of mammalian primordial germ cell proliferation. Biol Reprod 2003;20:1989-1997.
31. Atchison FW, Capel B, Means AR. Pin1 regulates the timing of mammalian primordial germ cell proliferation. Development 2003;130:3579-3586.
32. Wulf G, Garg P, Liou YC, Iglehart D, Lu KP. Modeling breast cancer in vivo and ex vivo reveals an essential role of Pin1 in tumorigenesis. EMBO J 2004;23:3397-3407.
33. Bao L, Sauter G, Sowadski J, Lu KP, Wang D. Prevalent overexpression of prolyl isomerase Pin1 in human cancers. Am J Pathol 2004;164:1727-1737.
34. Pang R, Yuen J, Yuen MF, et al. PIN1 overexpression and beta-catenin gene mutations are distinct oncogenic events in human hepatocellular carcinoma. Oncogene 2004;23: 4182-4186.
35. Yeh E, Cunningham M, Arnold H, et al. A signaling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat Cell Biol 2004;6:308-318.
36. Yi P, Wu RC, Sandquist J, et al. Peptidyl-prolyl isomerase 1 (Pin 1) serves as a coactivator of steroid receptor by regulating the activity of phosphorylated steroid receptor coactivator 3 (SRC-3/AIB1). Mol Cell Biol 2005;25:9687-9699.
37. Suizu F, Ryo A, Wulf G, Lim J, Lu KP. Pin1 regulates centrosome duplication and its overexpression induces centrosome amplification, chromosome instability and oncogenesis. Mol Cell Biol 2006;26:1463-1479.
38. Nevins JR. The Rb/E2F pathway and cancer. Hum Mol Genet 2001;10:699-703.
39. Ryo A, Suizu F, Yoshida Y, et al. Regulation, of NF-kappaB signaling by Pin1-dependent prolyl isomerization and ubiquitin-mediated proteolysis of p65/RelA. Mol Cell 2003; 12:1413-1426.
40. Miyashita H, Mori S, Motegi K, Fukumoto M, Uchida T. Pin1 is overexpressed in oral squamous cell carcinoma and its levels correlate with cyclin D1 overexpression. Oncol Rep 2003; 10:455-461.
41. Nakashima M, Meirmanov S, Naruke Y, et al. Cyclin D1 overexpression in thyroid tumours from a radio-contaminated area and its correlation with Pin1 and aberrant beta-catenin expression. J Pathol 2004;202:446-455.
42. Sherr CJ. Cancer cell cycles. Science 1996;274:1672-1677.
43. Yu Q, Geng Y, Sicinski P. Specific protection against breast cancers by cyclin D1 ablation. Nature 2001;411:1017-1021.
44. Lamb J, Ramaswamy S, Ford HL, et al. A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer. Cell 2003;114:323-334.
45. Alt JR, Cleveland JL, Hannink M, Diehl JA. Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation. Genes Dev 2000;14: 3102-3114.
46. Dougherty MK, Müller J, Ritt DA, et al. Regulation of Raf-1 by direct feedback phosphorylation. Mol Cell 2005;17: 215-224.
47. Doxsey S, McCollum D, Theurkauf W. Centrosomes in cellular regulation. Annu Rev Cell Dev Biol 2005.
48. Salisbury JL, D'Assoro AB, Lingle WL. Centrosome amplification and the origin of chromosomal instability in breast cancer. J Mammary Gland Biol Neoplasia 2004;9:275-283.
49. Nigg EA. Centrosome aberrations: Cause or consequence of cancer progression? Nat Rev Cancer 2002;2:815-825.
50. Bornens M. Centrosome composition and microtubule anchoring mechanisms. Curr Opin Cell Biol 2002;14:25-34.
51. Hinchdiffe EH, Sluder G. "It takes two to tango": Understanding how centrosome duplication is regulated throughout the cell cycle. Genes Dev 2001;15:1167-1181.
52. Doxsey S, Zimmerman W, Mikule K. Centrosome control of the cell cycle. Trends Cell Biol 2005;15:303-311.
53. D'Assoro AB, Lingle WL, Salisbury JL. Centrosome amplification and the development of cancer. Oncogene 2002;21: 6146-6153.
54. Goepfert TM, Adigun YE, Zhong L, Gay J, Medina D, Brinkley WR. Centrosome amplification and overexpression of aurora A are early events in rat mammary carcinogenesis. Cancer Res 2002;62:4115-4122.
55. Pihan GA, Purohit A, Wallace J, et al. Centrosome defects and genetic instability in malignant tumors. Cancer Res 1998;58:3974-3985.
56. Lingle WL, Lutz WH, Ingle JN, Maihle NJ, Salisbury JL. Centrosome hypertrophy in human breast tumors: Implications for genomic stability and cell polarity. Proc Natl Acad Sci USA 1998;95:2950-2955.
57. Pihan GA, Doxsey SJ. The mitotic machinery as a source of genetic instability in cancer. Semin Cancer Biol 1999;9:289-302.
58. Lingle WL, Salisbury JL. Altered centrosome structure is associated with abnormal mitoses in human breast tumors. Am J Pathol 1999;155:1941-1951.
59. Ghadimi BM, Sackett DL, Difilippantonio MJ, et al. Centrosome amplification and instability occurs exclusively in aneuploid, but not in diploid colorectal cancer cell lines, and correlates with numerical chromosomal aberrations. Genes Chromosomes Cancer 2000;27:183-190.
60. Sato N, Mizumoto K, Nakamura M, et al. Correlation between centrosome abnormalities and chromosomal instability in human pancreatic cancer cells. Cancer Genet Cytogenet 2001;126:13-19.
61. Lingle WL, Barrett SL, Negron VC, et al. Centrosome amplification drives chromosomal instability in breast tumor development. Proc Natl Acad Sci USA 2002;99:1978-1983.
62. D'Assoro AB, Barrett SL, Folk C, et al. Amplified centrosomes in breast cancer: A potential indicator of tumor aggressiveness. Breast Cancer Res Treat 2002;75:25-34.
63. Pihan GA, Wallace J, Zhou Y, Doxsey SJ. Centrosome abnormalities and chromosome instability occur together in pre-invasive carcinomas. Cancer Res 2003;63:1398-1404.
64. Pihan GA, Purohit A, Wallace J, Malhotra R, Liotta L, Doxsey SJ. Centrosome defects can account for cellular and genetic changes that characterize prostate cancer progression. Cancer Res 2001;61:2212-2219.
65. Shen M, Stukenberg PT, Kirschner MW, Lu KP. The essential mitotic peptidyl-prolyl isomerase Pin1 binds and regulates mitosis-specific phosphoproteins. Genes Dev 1998;12:706-720.
66. Rippmann JF, Hobbie S, Daiber C, et al. Phosphorylation-dependent proline isomerization catalyzed by Pin1 is essential for tumor cell survival and entry into mitosis. Cell Growth Differ 2000;11:409-416.
67. Ryo A, Uemura H, Ishiguro H, et al. Stable suppression of tumorigenicity by Pin1-targeted RNA interference in prostate cancer. Clin Cancer Res 2005;11:7523-7531.
68. Fujimori F, Takahashi K, Uchida C, Uchida T. Mice lacking Pin1 develop normally, but are defective in entering cell cycle from G(0) arrest. Biochem Biophys Res Commun 1999;265: 658-663.
69. Hennig L, Christner C, Kipping M, et al. Selective inactivation of parvulin-like peptidyl-prolyl cis/trans isomerases by juglone. Biochemistry 1998;37:5953-5960.
70. Uchida T, Takamiya M, Takahashi M, et al. Pin1 and Par14 peptidyl prolyl isomerase inhibitors block cell proliferation. Chem Biol 2003;10:15-24.
71. Chao SH, Greenleaf AL, Price DH. Juglone, an inhibitor of the peptidyl-prolyl isomerase Pin1, also directly blocks transcription. Nucleic Adcis Res 2001;29:767-773.